Transcription of The Diagnosis and Management of Nonalcoholic Fatty Liver ...
{{id}} {{{paragraph}}}
The Diagnosis and Management ofNonalcoholic Fatty Liver Disease:Practice Guidance From the AmericanAssociation for the Study ofLiver DiseasesNaga Chalasani,1 Zobair Younossi,2 Joel E. Lavine,3 Michael Charlton,4 Kenneth Cusi,5 Mary Rinella,6 Stephen A. Harrison,7 Elizabeth M. Brunt,8and Arun J. Sanyal9 PreambleThis guidance provides a data-supported approach tothe diagnostic, therapeutic, and preventive aspects ofnonalcoholic Fatty Liver disease (NAFLD) care. A Guidance document is different from a Guideline. Guidelinesare developed by a multidisciplinary panel ofexperts and rate the quality (level) of the evidence andthe strength of each recommendation using the GradingAbbreviations: AASLD, american Association for the Study of Liver Diseases; ACG, american College of gastroenterology ; AIH, autoimmune hepa-titis; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; AUROC, area under the receiver operatingcurve; BMI, body mass index; CI, confidence interval; CLD, chronic Liver disease; CT, computed tomography; CVD, cardiovascular disease; ELF,Enhanced Liver Fibrosis; FDA, Food and Drug Administration; FIB-4, fibrosis-4 index; FLD, Fatty Liver disease; GFR, glomerular filtrationrate; GLP-1, glucagon-like peptide-1; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
American Association for the Study of Liver Diseases (AASLD) and is an update to the Practice Guideline published in 2012 in conjunction with the American Gastroenterology Association and the American Col-lege of Gastroenterology (ACG).(1) Sections where there have been no notable newer publications are not modified, so some paragraphs remain ...
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}